SBTi Registry
Explore 1 matching companies with public, verified Science Based Targets commitments.
Data sourced from the Science Based Targets initiative (SBTi).
| Sector | Region | Near-Term Status | Size | ||||
|---|---|---|---|---|---|---|---|
| Piramal Pharma Limited | Pharmaceuticals, Biotechnology and Life Sciences | Asia | Targets set | Large | 3 | Sep 12, 2024 | |
Near-Term Status Targets set Near-Term Classification 1.5°C Near-Term Target Year - Long-Term Status - Net-Zero Status - Net-Zero Year - Sector Pharmaceuticals, Biotechnology and Life Sciences Region Asia Organization Type Corporate Location India Company Size Large Target Statement Piramal Pharma Limited commits to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year.* Piramal Pharma Limited also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream trans… Stakeholders Vamsi Krishna Sarangalwar Deputy Chief Manager - Energy Management and Decarbonization (Global Engineering) Ganesh Tripathy Senior Vice President and Global Head - Sustainability & EHS ESG Lead | |||||||
Turn Commitments Into Impact
Thousands of companies have set public Scope 3 emissions-reduction targetsthrough SBTi, but few have the tools to deliver on them. Carbon3 gives you the infrastructure to plan, track, and execute the supply-chain decarbonization work behind your commitment, turning a public pledge into measurable progress. See how it works.